Concepedia

Impact of the epidermal growth factor receptor mutation status on the post-recurrence survival of patients with surgically resected non-small-cell lung cancer

Tomoyoshi Takenaka, Mitsuhiro Takenoyama, Masafumi Yamaguchi, Ryo Toyozawa, Eiko Inamasu, Miyako Kojo, Gouji Toyokawa, Tsukihisa Yoshida, Yoshimasa Shiraishi, Yosuke Morodomi,

European Journal of Cardio-Thoracic Surgery · 2014 · 34 citations · 21 references

DOIFull text

Open access

Abstract

It is essential for recurrent NSCLC patients to be examined for the EGFR mutation status. Patients with a positive EGFR mutation status receive significant benefits from EGFR-TKI therapy.

References

21

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

Jacques Ferlay, Hai‐Rim Shin, Freddie Bray et al. · International Journal of Cancer · 2010 · 21.3K citations

, , +16

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Thomas J. Lynch, Daphne W. Bell, Raffaella Sordella et al. · New England Journal of Medicine · 2004 · 11.4K citations

<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

J. Guillermo Paez, Pasi A. Jänne, Jeffrey C. Lee et al. · Science · 2004 · 9.4K citations

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

Makoto Maemondo, Akira Inoue, Kunihiko Kobayashi et al. · New England Journal of Medicine · 2010 · 5.5K citations

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rafael Rosell, Enric Carcereny, Radj Gervais et al. · The Lancet Oncology · 2012 · 5.5K citations · Full text

, , +8